Novo Holdings led GlycoEra AG’s $130M Series B financing, which will support the advancement of the company’s first-in-class extracellular protein degrader – GE8820 – which targets pathogenic IgG4 autoantibodies. GE8820 has shown deep and sustained IgG4 degradation in preclinical models, offering a highly selective and transformative approach to treating conditions such as pemphigus, MuSK myasthenia gravis, and autoimmune encephalitis. In association with this investment, Novo Holdings Partner Max Klement will join GlycoEra’s Board of Directors to support the company through its evolution from a platform innovator to a clinical-stage biotech advancing multiple products across its pipeline. Learn more about GlycoEra here: https://lnkd.in/d2D99vhi #VentureInvestments #Biotech #LifeSciences
Eric Snyder
1mo
Congratulations Max Klement and GlycoEra AG!
AKSHAY KUMAR
1mo
Novo Holdings A remarkable leap forward in immunology and targeted biologics! Congratulations to GlycoEra AG and Novo Holdings on this strategic $130M Series B funding round. The advancement of GE8820 as a first-in-class extracellular protein degrader targeting pathogenic IgG4 autoantibodies has immense potential to reshape treatment paradigms for autoimmune diseases like pemphigus, MuSK myasthenia gravis, and autoimmune encephalitis. At MedTech World, we’re committed to supporting and amplifying such breakthroughs on a global scale bringing together innovators, investors, and healthcare leaders across Europe, Asia, and North America. Novo HoldingsLet’s connect and explore how this novel science can gain broader visibility and access in underserved markets worldwide. MedTech World #HealthTech #AutoimmuneDiseases #ProteinDegradation #BiotechInnovation #IgG4 #PrecisionMedicine #Immunotherapy #GE8820 #MedTechWorld #DigitalHealth #ClinicalInnovation #GlobalHealthcare #VentureCapital #LifeSciences #TherapeuticInnovation #NextGenBiologics #CrossBorderHealthcare #FutureOfMedicine
Natalia Novac
1mo
Congratulations Max Klement and GlycoEra Team!
Partner at BGV - Biotech Investor
1moExciting deal, Max! Will follow you closely